{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T18:49:57Z","timestamp":1783536597763,"version":"3.55.0"},"reference-count":20,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2020,9,10]],"date-time":"2020-09-10T00:00:00Z","timestamp":1599696000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clin Exp Pharma Physio"],"published-print":{"date-parts":[[2020,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>A novel concept in DNA vaccine design is the creation of an inhaled DNA plasmid construct containing a portion of the coronavirus spike protein for treatment and vaccination. The secretion of a spike protein portion will function as a competitive antagonist by interfering with the binding of coronavirus to the angiotensin\u2010converting enzyme 2 (ACE2) receptor. The secreted protein binding to the ACE2 receptor provides a unique mechanism of action for treatment to all strains of coronavirus in na\u00efve patients, by blocking the ACE2 receptor site. An inhaled plasmid DNA vaccine replicates the route of lung infection taken by coronavirus with transfected cells secreting spike protein portions to induce immunity. Unlike most DNA vaccines with intracellular antigen presentation through MHC I, the current vaccine relies on the secreted proteins presentation through MHC II as well as MHC I to induce immunity. Lung specific production of vaccine particles by inhaled plasmid DNA is appealing since it may have limited systemic side effects, and may induce both humoral and cytotoxic immunity. Finally, the ease and ability to rapidly produce this plasmid construct makes this an ideal solution for managing the emerging threat of coronavirus.<\/jats:p>","DOI":"10.1111\/1440-1681.13393","type":"journal-article","created":{"date-parts":[[2020,8,8]],"date-time":"2020-08-08T07:46:21Z","timestamp":1596872781000},"page":"1874-1878","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["A novel concept for treatment and vaccination against Covid\u201019 with an inhaled chitosan\u2010coated DNA vaccine encoding a secreted spike protein portion"],"prefix":"10.1111","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5871-4573","authenticated-orcid":false,"given":"Dean","family":"Tatlow","sequence":"first","affiliation":[{"name":"Calgary Alberta Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corinne","family":"Tatlow","sequence":"additional","affiliation":[{"name":"Calgary Alberta Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scarlet","family":"Tatlow","sequence":"additional","affiliation":[{"name":"Calgary Alberta Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Savanah","family":"Tatlow","sequence":"additional","affiliation":[{"name":"Calgary Alberta Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,9,10]]},"reference":[{"key":"e_1_2_6_2_1","first-page":"1","article-title":"Characterization of the receptor\u2010binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine","volume":"2020","author":"Tai W","year":"2019","journal-title":"Cell Mol Immunol"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02631-07"},{"key":"e_1_2_6_4_1","first-page":"1","volume-title":"Methods in Molecular Biology","author":"Fehr AR","year":"2015"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.8456302"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines7020037"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.abc6284"},{"key":"e_1_2_6_8_1","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/S0140-6736(17)33105-7","article-title":"Safety, tolerability, and immunogenicity of two Zika virus DNA vaccine candidates in healthy adults: randomised, open\u2010label, phase 1 clinical trials","volume":"391","author":"Gaudinski MR","year":"2017","journal-title":"Lancet"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-med-040717-051127"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2017.197"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics6030378"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1021\/mp200553x"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0152386"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.C300520200"},{"key":"e_1_2_6_15_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fimmu.2019.01323","article-title":"Airway M cells arise in the lower airway due to RANKL signaling and reside in the bronchiolar epithelium associated with iBALT in murine models of respiratory disease","volume":"10","author":"Kimura S","year":"2019","journal-title":"Front Immunol"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1300504"},{"key":"e_1_2_6_17_1","doi-asserted-by":"crossref","first-page":"144","DOI":"10.3390\/vaccines7040144","article-title":"Dose effects of recombinant adenovirus immunization in rodents","volume":"7","author":"Weaver EA","year":"2019","journal-title":"Vaccines"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics11080375"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12951-018-0337-2"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics12060540"},{"issue":"3","key":"e_1_2_6_21_1","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1073\/pnas.0409065102","article-title":"Evasion of antibody neutralization in emerging severeacute respiratory syndrome coronaviruses","volume":"102","author":"Yang ZY","year":"2005","journal-title":"Proc Natl Acad Sci USA"}],"container-title":["Clinical and Experimental Pharmacology and Physiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2F1440-1681.13393","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1440-1681.13393","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/1440-1681.13393","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1440-1681.13393","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,4]],"date-time":"2023-09-04T06:34:18Z","timestamp":1693809258000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1440-1681.13393"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,10]]},"references-count":20,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["10.1111\/1440-1681.13393"],"URL":"https:\/\/doi.org\/10.1111\/1440-1681.13393","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.1111\/1440-1681.13393\/v4\/response1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/1440-1681.13393\/v2\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/1440-1681.13393\/v4\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/1440-1681.13393\/v2\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/1440-1681.13393\/v3\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/1440-1681.13393\/v4\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/1440-1681.13393\/v3\/response1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/1440-1681.13393\/v2\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/1440-1681.13393\/v1\/review3","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/1440-1681.13393\/v1\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/1440-1681.13393\/v1\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/1440-1681.13393\/v1\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/1440-1681.13393\/v3\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/1440-1681.13393\/v2\/response1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/1440-1681.13393\/v3\/review1","asserted-by":"object"}]},"ISSN":["0305-1870","1440-1681"],"issn-type":[{"value":"0305-1870","type":"print"},{"value":"1440-1681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,10]]},"assertion":[{"value":"2020-04-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-07-31","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-09-10","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}